Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares
Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 5,109 Class A shares at no cash cost under the company’s Outside Director Compensation Policy. Following this award, Dar directly holds 240,764 Class A shares. This transaction was reported in a Form 4 filing and categorized as an acquisition reflecting standard director compensation.
Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant
Recursion (NASDAQ: RXRX) director Dean Y. Li has received an equity grant of 3,747 Class A shares as compensation under the company’s Outside Director Compensation Policy. This grant increases his direct holdings to 1,473,329 Class A shares. Additionally, Li indirectly holds 421,000 Class A shares through the Dean Y. Li 2021 Family Trust and 1,422,048 Class A shares through the Dean Y. Li Revocable Trust.
Christopher C. Gibson lists multiple Class A sales (RXRX)
Christopher C. Gibson, an insider at Recursion Pharmaceuticals, Inc. (RXRX), has filed a Form 144 notice for proposed sales of Class A common stock. The filing details several disposition dates and share quantities, including a significant 100,000 share entry dated July 1, 2026, and a 340,440 share entry from June 18, 2026. These are proposed transactions rather than completed sales.
RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares
Recursion Pharmaceuticals (NASDAQ: RXRX) has filed a Form 144 disclosing a prospective sale of 100,000 Class A shares resulting from restricted stock vesting on May 15, 2025. The filing also notes previous dispositions by Christopher C. Gibson, including 340,440 shares sold for over $1 million between April and June 2026. This notice is an administrative intent to sell and does not confirm actual sale completion.
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
GT Biopharma, Inc. (NASDAQ: GTBP) is leveraging AI-based tools to accelerate its drug discovery and engineering efforts, expecting multiple new development candidates to enter pre-IND development in 2027. This strategy aims to improve efficiency, reduce costs, and shorten timelines in designing tumor-targeting drugs, expanding potential indications beyond oncology. The update comes as the company advances two TriKE candidates, GTB-3650 and GTB-5550, through Phase 1 clinical trials, highlighting a dual focus on current clinical execution and building a faster, cheaper pipeline for the future.
Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX)
This article provides an overview of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding the stock's ticker, price volatility, earnings reports, revenue, net income, and dividend policy. The article also provides guidance on how to buy RXRX stocks through online brokers and advises on due diligence before investing.
8RL Forecast — Price Target — Prediction for 2027
This article provides a forecast for Recursion Pharmaceuticals, Inc. Class A (8RL) stock, including a price target of 5.69 EUR based on analyst estimates. It outlines key financial metrics such as recent earnings and revenue, and provides information on employee count and EBITDA. The report also addresses frequently asked questions about the stock, including how to buy shares and upcoming earnings dates.
RXRX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Recursion Pharmaceuticals, Inc. (RXRX) stock, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings and revenue, and answers common questions about its stock performance, market capitalization, and upcoming earnings dates.
Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grant
Recursion Pharmaceuticals (NASDAQ: RXRX) director Robert Hershberg was granted 88,424 restricted stock units (RSUs) as a routine award under the company’s Outside Director Compensation Policy. These RSUs vest on the earlier of June 17, 2027, or the day before the company’s 2027 annual stockholder meeting, contingent on his continued service. Following this grant, Hershberg directly holds 162,156 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) director gets 88,424 RSUs, sells 3,963 shares
Recursion Pharmaceuticals, Inc. director Namandje Bumpus received a grant of 88,424 restricted stock units (RSUs) on June 17, 2026, which vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholders’ meeting. Concurrently, on June 18, 2026, Bumpus sold 3,963 shares of Class A Common Stock at $3.18 per share through a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Bumpus directly owns 127,632 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) director Elaine Sun receives 88,424 restricted stock units
Recursion Pharmaceuticals (NASDAQ: RXRX) director Elaine Sun has been granted 88,424 restricted stock units (RSUs) as an equity award, with no cash cost, under the company’s Outside Director Compensation Policy. These RSUs will vest on the earlier of June 17, 2027, or the day before the 2027 Annual Meeting of Stockholders, contingent on her continued service. Following this transaction, Sun directly holds 135,981 shares of Class A Common Stock.
Recursion (RXRX) director Zavain Dar granted 88,424 restricted stock units
Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 88,424 restricted stock units (RSUs) for board service. These RSUs, valued at $0.00 per share, will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on continued service. Following this transaction, Dar's direct holdings in Recursion Pharmaceuticals Class A Common Stock amount to 235,655 shares.
Recursion (RXRX) director receives 88,424 restricted stock units award
Recursion Pharmaceuticals (RXRX) director Blake Borgeson was granted 88,424 restricted stock units of Class A common stock under the company’s Outside Director Compensation Policy. These units will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on his continued service. This award increases his direct holdings to 6,258,287 shares.
Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units
Recursion Pharmaceuticals (NASDAQ: RXRX) director Franziska Michor was granted 88,424 restricted stock units as compensation under the company's Outside Director Compensation Policy. These units were granted at $0.00 per share and will vest on June 17, 2027, or the day before the company's 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, Michor directly holds 215,477 shares of the company’s Class A Common Stock.
Recursion (NASDAQ: RXRX) director Dean Y. Li granted 88,424 RSUs, updates holdings
Recursion (NASDAQ: RXRX) director Dean Y. Li was granted 88,424 restricted stock units (RSUs) as part of the company's Outside Director Compensation Policy. These RSUs, valued at $0.00 per share, are set to vest on June 17, 2027, or the day before the 2027 Annual Meeting of Stockholders, provided Mr. Li continues his service. Following this grant, Dean Y. Li's direct holdings in Class A Common Stock now total 1,469,582 shares, in addition to substantial indirect holdings through family trusts.
Recursion Pharmaceuticals (RXRX) Proxy filing Summary
Recursion Pharmaceuticals (RXRX) will hold its annual meeting virtually on June 17, 2026, where shareholders will vote on the election of two Class II directors, executive compensation, and auditor ratification. The company, a clinical-stage TechBio firm, uses AI for drug discovery and development. The board recommends approval of all proposals, emphasizing shareholder participation.
Recursion (NASDAQ: RXRX) investors back board nominees and PwC as 2026 auditor
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shareholders approved all management proposals at their 2026 annual meeting on June 17, 2026. Shareholders re-elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., and advisory approved executive compensation. They also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, demonstrating continued support for the company's governance and compensation practices.
RXRX (NASDAQ) proposed resale of multiple 40,000-share blocks between Mar–Jun 2026
RXRX (Recursion Pharmaceuticals, INC.) has filed a Form 144, indicating proposed resales of Class A founder shares. The filing details multiple 40,000-share blocks with potential trade dates spanning from March to June 2026, each with an associated dollar value. Fidelity Brokerage Services LLC is listed as the broker for these transactions, which are described as compensation-originated or founder-held shares.
Christopher C. Gibson sells six 40,000-share lots (RXRX) across Mar–Jun 2026
Christopher C. Gibson, an insider at Recursion Pharmaceuticals (RXRX), filed a Form 144 detailing six separate sales of 40,000 Class A shares each between March and June 2026. The filing also indicates scheduled restricted stock vesting events for Class A shares in 2025 and 2026. Analysts describe these transactions as routine dispositions, with explicit share counts and gross proceeds noted for each sale.
RXRX (NASDAQ) affiliate files Form 144 to sell 3,963 Class A shares
An affiliate of Recursion Pharmaceuticals (RXRX) has filed a Form 144, indicating an intent to sell 3,963 Class A shares resulting from restricted stock vesting on June 18, 2026. This filing also discloses a prior sale of 4,386 Class A shares by Namandje Bumpus on June 3, 2026. The filing is a routine disclosure related to compensation and vests shares, rather than a strategic sale.
Recursion (NASDAQ: RXRX) CFO covers taxes with 5,396 withheld shares
Recursion Pharmaceuticals' CFO, Ben R. Taylor, reported a tax-related disposition where 5,396 shares of Class A Common Stock were withheld to cover tax obligations stemming from restricted stock units. The shares were withheld at a price of $3.15 per share. Following this transaction, Taylor directly holds 1,101,876 shares of Class A Common Stock.
Recursion Pharmaceuticals (RXRX) Stock Could Be 67% Overvalued After Pipeline Updates
Recursion Pharmaceuticals (RXRX) is gaining attention due to recent clinical updates and an upcoming presentation at the Goldman Sachs Global Healthcare Conference, leading to a recent share price increase. Despite this, some analyses suggest the stock is significantly overvalued, with a fair value estimate of $1.97 compared to the current $3.29, driven by an aggressive growth narrative. However, a discounted cash flow model suggests a higher value of $9.09, indicating conflicting views on the stock's true potential amidst ongoing net losses and past underperformance.
Early Safety Data And FDA Signals Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals' investment case is being reshaped by early safety data for REC-1245 in solid tumors and anticipated FDA feedback on REC-4881, which are key catalysts for its AI-driven drug discovery platform. While the initial safety profile of REC-1245 is positive, investor focus remains on translating AI tools into clinical and regulatory outcomes amidst ongoing cash burn. The article suggests that Recursion's forecasts yield a significant upside to its current price, but also highlights the need to consider risks and other perspectives.
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway
Recursion Pharmaceuticals (RXRX) saw its stock rise by 9.5% following positive early clinical data from its AI-driven drug discovery programs and a reduced cash burn, extending its capital runway into early 2028. This progress suggests its integrated TechBio model is yielding tangible results, strengthening its investment narrative. While the company's Q1 2026 update showed better-than-expected earnings and a narrower net loss, investors are cautioned that the early-stage pipeline still requires substantial future funding.
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com
Najat Khan, CEO of Recursion Pharmaceuticals, sold 23,588 shares of RXRX stock for $84,459 on June 5, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Khan directly holds over 2.17 million shares, and the company has a market cap of $1.77 billion. The article also mentions recent Q1 2026 earnings, which beat EPS estimates but missed revenue targets, and the potential impact of AI on reducing drug development costs.
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock
Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock for $84,459 on June 5, 2026, as part of a pre-arranged trading plan. Following the sale, Ms. Khan retains over 2.1 million shares. The company recently reported mixed first-quarter 2026 earnings, with higher-than-expected EPS but a significant revenue shortfall, while the broader industry recognizes AI's potential for cost reduction in drug development.
Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade
Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Khan still directly holds a significant 2,175,796 shares. This transaction, detailed in a Form 4 SEC filing, ensures transparency around insider trading.
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan
A director at Recursion Pharmaceuticals (NASDAQ: RXRX), Christopher Gibson, sold 40,000 shares of Class A Common Stock at $3.62 per share on June 5, 2026. This transaction was executed under a pre-planned Rule 10b5-1 trading plan adopted in May 2025 and followed an automatic conversion of Class B shares to Class A shares. Despite the sale, Gibson retains a significant holding of both Class A and Class B shares in the company.
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock
Najat Khan, CEO of Recursion Pharmaceuticals (NASDAQ:RXRX), sold 23,588 shares of company stock for $84,459 on June 5, 2026, through a pre-arranged trading plan. Following this transaction, Ms. Khan still holds over 2.1 million shares. The sale occurred amidst recent company news, including mixed Q1 2026 earnings and a report highlighting AI's potential to significantly cut drug development costs.
Recursion Pharma director Christopher Gibson sells $144,800 in stock
Christopher Gibson, a director at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 40,000 shares of Class A Common Stock for $144,800 on June 5, 2026, under a Rule 10b5-1 trading plan. This transaction occurred as RXRX shares were trading at $3.32, significantly below their 52-week high. Prior to the sale, Gibson converted Class B shares to Class A shares and still holds a substantial number of shares and stock options.
Gibson files Form 144 to sell 40,000 Class A shares (RXRX)
Christopher C. Gibson has filed a Form 144 indicating a proposed sale of 40,000 Class A shares of Recursion Pharmaceuticals, Inc. (RXRX). The filing also details multiple past sales of 40,000 Class A shares each during March, April, and May 2026, with specific proceeds reported for each transaction. This filing provides transparency regarding potential insider stock sales and their financial impact.
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan
Recursion Pharmaceuticals director Namandje Bumpus sold 4,386 shares of Class A common stock at an average price of $3.54 per share under a pre-planned Rule 10b5-1 trading plan. After this transaction, Bumpus still directly holds 43,171 shares. This sale represents a portion of the director’s overall stake and is considered a routine diversification rather than a strong directional signal for investors.
Recursion (NASDAQ: RXRX) director sells 30,000 shares under 10b5-1 plan
Blake Borgeson, a director at Recursion Pharmaceuticals (NASDAQ: RXRX), sold 30,000 shares of Class A Common Stock at $3.68 per share on June 2, 2026. This transaction, totaling $110,400, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. After the sale, Borgeson directly holds 6,169,863 shares of the company.
Recursion Pharma director Christopher Gibson sells $144,800 in stock
Christopher Gibson, a director at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), sold 40,000 shares of Class A Common Stock for $144,800 on June 5, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred while RXRX shares were trading at $3.32, significantly down from their 52-week high, though InvestingPro analysis suggests the stock is undervalued. Gibson continues to hold a substantial number of shares and stock options following the transaction, which was preceded by a conversion of Class B to Class A Common Stock.
RXRX (NASDAQ) affiliate sales reported: Borgeson sells 230,000 shares in 2026
Recursion Pharmaceuticals, Inc. (RXRX) submitted a Form 144 detailing proposed or reported sales of Class A shares by affiliate Blake C. Borgeson. Borgeson conducted multiple transactions in Spring 2026, totaling 230,000 shares across March, April, and May 2026, with sales amounting to $588,200, $93,000, and $105,600 respectively. The filing also notes a 2017 allocation of 30,000 Founder Shares and an entry for Fidelity Brokerage Services LLC.
Why Recursion Pharmaceuticals (RXRX) Is Up 7.1% After Extending Cash Runway And Advancing REC-4881
Recursion Pharmaceuticals' stock (RXRX) increased by 7.1% following news of an extended cash runway into early 2028 and promising Phase 2 efficacy data for its drug REC-4881 in familial adenomatous polyposis. This development strengthens the company's AI-driven drug discovery narrative and somewhat alleviates funding concerns, supporting the potential for its AI platform to generate clinically meaningful assets. While the positive data for REC-4881 is a significant near-term catalyst, investors are advised to weigh this against ongoing cash burn and the need for successful larger studies to solidify the bull case.
Recursion (NASDAQ: RXRX) director sells 40,000 shares in planned trade
A director at Recursion Pharmaceuticals (NASDAQ: RXRX), Christopher Gibson, sold 40,000 Class A shares on May 22, 2026, for $3.08 per share, totaling $123,200. This transaction followed the conversion of 40,000 Class B shares to Class A shares and was executed under a pre-scheduled Rule 10b5-1 trading plan adopted in May 2025. After the sale, Gibson directly holds 883,735 Class A shares and 4,303,334 Class B shares.
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Lose Momentum In Recent Months
Recursion Pharmaceuticals (RXRX) shares have seen a significant decline, down 19% in the past month and 12% in three months, raising questions about its valuation. While a prevailing narrative suggests the stock is 52.8% overvalued with a fair value of $1.97, Simply Wall St's Discounted Cash Flow (DCF) model indicates a potential undervaluation, estimating a future cash flow value of $9.04 against its current price of $3.01. This divergence highlights mixed sentiment and the need for investors to consider both analytical perspectives and fundamental data.
RXRX (NASDAQ) Form 144: 40,000 Class A shares proposed sale via Fidelity
RXRX (Recursion Pharmaceuticals, Inc.) has filed a Form 144 indicating a proposed sale of 40,000 Class A shares through Fidelity Brokerage Services LLC. The filing also details previous open-market sales by Christopher C. Gibson on several dates in early 2026, each for 40,000 shares with specified aggregate transaction amounts. These shares are identified as 'Founders Shares' originally acquired through compensation.
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 By Investing.com
Christopher Gibson, a director at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 40,000 shares of Class A Common Stock for $134,800 on May 7, 2026, as part of a Rule 10b5-1 trading plan. Despite a 25% stock decline over the past year, InvestingPro analysis indicates the company may be undervalued. Gibson also acquired 60,000 Class A shares via conversion and gifted 20,000 shares, maintaining a direct holding of over 900,000 Class A shares and indirect holdings through trusts.
Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet?
Recursion Pharmaceuticals reported Q1 2026 results with significant losses, emphasizing the need for clinical and partnership progress to justify its AI-driven drug discovery engine. Concurrently, Altitude Lab, co-founded by Recursion, announced its portfolio companies have raised over US$205 million and are advancing in clinical trials and pharma deals. This external validation could strengthen Recursion's investment narrative despite its high cash burn, underscoring the broader biotech ecosystem's role in its future.
Recursion Pharmaceuticals, Inc. Class A Trade Ideas — NASDAQ:RXRX
This article compiles various trading ideas and analyses for Recursion Pharmaceuticals (NASDAQ: RXRX), highlighting its potential as an AI-driven biopharma company despite current cash burn. Multiple contributors offer bullish outlooks based on technical patterns, strategic partnerships with giants like Nvidia and Roche, and the long-term vision of AI revolutionizing drug discovery, alongside some cautionary notes regarding its speculative nature.
Recursion (NASDAQ: RXRX) CSO RSU tax withholding on 26,657 shares
Recursion Pharmaceuticals' Chief Scientific Officer, David Hallett, reported a tax-related share disposition. A total of 26,657 shares of Class A Common Stock were withheld at $3.04 per share to cover tax obligations tied to restricted stock units. This was a routine administrative transaction, not an open-market sale, and Hallett retains 1,070,494 shares of Class A Common Stock after the event.
Recursion (NASDAQ: RXRX) CEO has 62,701 shares withheld for RSU taxes
Recursion CEO and President Najat Khan had 62,701 Class A Common Stock shares, valued at $3.04 each, withheld to cover tax obligations related to the net settlement of restricted stock units. This was a routine tax-related disposition, not an open-market sale. Following this transaction, Khan directly holds 2,199,384 shares of Class A Common Stock.
22,821 RXRX shares withheld for taxes as Recursion director reports RSU event
Recursion Pharmaceuticals director Christopher Gibson reported a tax-withholding transaction where 22,821 Class A Common Stock shares were withheld at $3.04 each to cover tax obligations from restricted stock unit settlements. This was not an open-market sale, and Gibson now directly holds 883,735 Class A shares. The filing also details various stock option grants and indirectly held Class B Common Stock through trusts and LLCs.
Recursion Pharmaceuticals (RXRX) CFO reports tax-related share withholding
Recursion Pharmaceuticals (RXRX) CFO Ben R. Taylor reported a tax-related share disposition where 25,018 Class A Common Stock shares were withheld at $3.04 per share. This withholding satisfied tax obligations arising from net-settled restricted stock units and was not an open-market sale. Following this transaction, Taylor directly owns 1,107,272 Class A shares.
Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX)
This article provides recent news headlines and financial updates for Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX). It lists various press releases from the company and related entities, covering topics such as financial results, business updates, strategic partnerships, and investor conference participation. The stock closed at 2.960, up 3.86%, as of May 20, 2026, 4:00 PM EDT.
Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX)
This article provides a list of recent news and press releases related to Recursion Pharmaceuticals Inc. (RXRX), covering various updates on their AI-driven drug discovery, financial results, investor conferences, and clinical trials. The news highlights breakthroughs in AI models for drug discovery, progress in therapeutic programs, and strategic collaborations.
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks
Recursion Pharmaceuticals (RXRX) recently reported their first-quarter 2026 results, showing a net loss of US$117.5 million, while founder Chris Gibson announced his departure from the board. Despite these developments, the company's investment narrative continues to revolve around its AI-driven drug discovery platform, with investors keenly watching FDA discussions regarding its pipeline, particularly REC-4881 for familial adenomatous polyposis. The article highlights both the potential for significant upside based on future revenue projections and the risks associated with ongoing cash burn and potential dilution.
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates
Recursion Pharmaceuticals (RXRX) is experiencing mixed signals in its valuation following recent clinical data updates and Q1 2026 results. While the stock has seen short-term gains, its long-term shareholder return has been negative. Conflicting valuation models show the stock as either significantly overvalued or undervalued, indicating uncertainty surrounding its future potential.
